Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of CP 870893 in patients with cancer.

Trial Profile

Phase II trial of CP 870893 in patients with cancer.

Phase of Trial: Phase II

Latest Information Update: 03 Sep 2012

At a glance

  • Drugs CP 870893 (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors VLST Corporation
  • Most Recent Events

    • 03 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top